Kevin Hudson

Oncology R&D, AstraZeneca
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4+ T Cells.

PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4+ T Cells.

Journal: Frontiers in immunology

Published: November 19, 2020

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.

Journal: Journal for immunotherapy of cancer

Published: September 21, 2018

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.

Journal: Oncotarget

Published: February 05, 2018

The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.

The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.

Journal: PloS one

Published: May 04, 2017

Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.

Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: April 21, 2017

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Journal: Blood

Published: December 20, 2016

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Journal: Science translational medicine

Published: December 07, 2016

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.

Journal: Bioorganic & medicinal chemistry letters

Published: September 11, 2015

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.

Journal: Molecular cancer therapeutics

Published: August 19, 2015

A Generic Platform for Cellular Screening Against Ubiquitin Ligases.

A Generic Platform for Cellular Screening Against Ubiquitin Ligases.

Journal: Scientific reports

Published: July 30, 2015

Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.

Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.

Journal: Journal of medicinal chemistry

Published: March 05, 2015

Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold.

Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold.

Journal: Bioorganic & medicinal chemistry letters

Published: March 04, 2015

Showing 1-12 of 16

Last Updated: 09/26/2026